Compare Cassava Sciences Inc (FLNA) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Noble Corporation plc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Noble Corporation plc trades at $42.28 (market cap $6.54B). The key difference: Noble Corporation plc is far larger — about 166× Cassava Sciences Inc's market cap, and Noble Corporation plc pays a 4.88% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Noble Corporation plc for 26 Days on average.
| FLNA | NE | |
|---|---|---|
Market Cap | $39.40M | $6.54B |
Volume | 759,018 | 1,192,391 |
Sector | Health | Energy |
52-Week High | $4.64 | $54.37 |
52-Week Low | $0.68 | $26.70 |
Typical Hold Time | 37 Days | 26 Days |
Enterprise Value | -$43.28M | $7.97B |
Dividend Yield | — | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Noble Corporation (NE) trades at $40.97, down 1.16% on the day, with a bearish technical signal driven by moving averages and ADX indicators. The stock's valuation shows a P/E of 43.59 and P/S of 2.14, while recent earnings have been mixed with two misses and one beat in the last three quarters. A long-term drilling contract in Ghana provides operational stability, but investor sentiment is tempered by an ongoing legal investigation noted in recent news.
The outlook for NE is cautious; analyst consensus is a Buy with a $52 price target, implying potential upside, but risks include earnings volatility and legal scrutiny. Positive cash flow and a dividend payment support income investors, yet the bearish technical trend and declining revenue in 2026 warrant close monitoring for any fundamental deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
